Newsroom
Investigation Commenced on Johnson & Johnson Stock, Investors Alerted
By KlickAnalytics Data Insights | January 10, 2025 08:05PM ET
Key Points
- Levi & Korsinsky, Pomerantz LLP, and Bronstein, Gewirtz & Grossman, LLC are all investigating Johnson & Johnson for potential securities law violations
- Johnson & Johnson paused U.S. External Evaluation and VARIPULSE™ cases due to reported neurovascular events
- JNJ stock underperformed in 2024, losing 7% while S&P 500 gained 23%
- FDA accepted J&J's filing for autoimmune disease drug Nipocalimab
- Dow Jones Industrial Average reached record highs, impacting J&J stock performance
Levi & Korsinsky, Pomerantz LLP, and Bronstein, Gewirtz & Grossman, LLC have all initiated investigations into Johnson & Johnson (JNJ) for potential violations of federal securities laws. This comes after J&J announced a temporary pause on the U.S. External Evaluation and VARIPULSE™ cases in response to four reported neurovascular events. Investors who have lost money on their Johnson & Johnson investment are encouraged to contact these firms for further information and assistance.
In 2024, Johnson & Johnson stock (JNJ) experienced a loss of around 7%, significantly underperforming the broader S&P 500 index, which saw a gain of 23% during the same period. This poor performance contrasts with other pharmaceutical giants like Eli Lilly and AbbVie, who saw stock increases of 31% and 15% respectively. Investors are now left wondering what the future holds for JNJ stock in 2025.
Additionally, J&J recently made a filing seeking FDA approval for nipocalimab, an autoimmune disease drug intended to treat generalized myasthenia gravis in a wide range of antibody-positive patients. This development could have significant implications for the company's future performance and stock value.
As the Dow Jones Industrial Average continues to reach record highs, surpassing 45,000 in December 2024, the broader market conditions have a direct impact on the performance of individual stocks like Johnson & Johnson. Investors are advised to monitor market trends and developments closely to make informed decisions regarding their investment portfolios.
For more information:
Ask the market a question. Get a calculated answer.
The AI is not a chatbot bolted onto a document store. It calls the same analytics engine that powers every screen on this platform — so what comes back is a number it computed from raw history, with the command that produced it.
86,000+ instruments
Global equities, ETFs, funds, options, FX, commodities, crypto, economics, filings, transcripts and news — one normalised symbol universe with adjusted history.
A real analytics engine
Screening, backtesting, technicals, options analytics, correlations, seasonality and factor models — computed on demand from raw prices, never a stale cache.
It shows its working
Answers arrive with the charts, tables and tool calls behind them, so you can check the number instead of trusting a paraphrase.
Your own documents
Upload filings, decks and research. Ask across them and the answer cites the page it came from.
Agents and workflows
Multi-step research that runs the platform's tools for you — screen, pull the history, compute, compare, then write it up.
MCP, CLI and API
The same command catalogue from Claude, your own agent, a shell or your pipeline. The answer on screen is the answer your job gets at 4am.
You ask
“How does NVDA usually trade through earnings?”
It calls
→ ka.options_expected_move(NVDA)
It answers
NVDA has averaged a 9.2% absolute move on the day after earnings and closed higher 67% of the time. Two in three reactions land between −4.2% and +16.3% — the distribution is skewed right, not symmetric.
Every figure computed live from our own history — not scraped, not summarised.
Or start with